Given that LRP6 is a positive regulator for osteoblastic bone formation,7,34,35 and that patients with autosomal dominant LRP6 mutations developed simultaneous early onset atherosclerosis and osteoporosis, it is possible that oxPLs directly target LRP6 in bone cells during hyperlipidemia/atherosclerosis. Here, LRP6 is linked to hyperlipidemia.